C&W Three-Year Cumulative Antibiogram January 2013 December 2015

Size: px
Start display at page:

Download "C&W Three-Year Cumulative Antibiogram January 2013 December 2015"

Transcription

1 C&W Three-Year Cumulative Antibiogram January 213 December 215 Division of Microbiology, Virology & Infection Control Department of Pathology & Laboratory Medicine Contents Comments and Limitations... 2 Contacts... 2 Achromobacter species... 3 Acinetobacter species... 3 Bacillus species... 4 Burkholderia cepacia complex... 4 Campylobacter jejuni... 5 Chryseobacterium species... 5 Citrobacter freundii... 6 Citrobacter koseri... 6 Corynebacterium species... 7 Elizabethkingia species... 7 Enterobacter aerogenes... 8 Enterobacter cloacae complex... 8 Enterococcus faecalis... 9 Enterococcus faecium... 9 Escherichia coli... 1 Haemophilus influenzae... 1 Klebsiella oxytoca Klebsiella pneumoniae Morganella morganii Pantoea species Propionibacterium species Proteus mirabilis Pseudomonas aeruginosa Pseudomonas fluorescens group Pseudomonas putida group Serratia marcescens Salmonella species Staphylococcus aureus Methicillin-Resistant Staphylococcus aureus Staphylococcus epidermidis Staphylococcus capitis (coagulase-negative) Staphylococcus lugdunensis Stenotrophomonas maltophilia Streptococcus pyogenes (Group A Strep)... 2 Streptococcus agalactiae (Group B Strep)... 2 Streptococcus dysgalactiae (Groups C & G) Streptococcus pneumoniae Streptococcus mitis group (viridans Strep) Streptococcus anginosis group July 28 th, 216 1

2 Usage New technology in Microbiology (MALDI-TOF mass spectrometry) has reduced the time needed to identify organisms, but definitive susceptibility testing results still require a further 1-2 days. In the interim, antibiogram data may be useful in choosing or optimizing antibiotics to help ensure adequate coverage for the organism of interest. Please keep in mind previous antimicrobial therapy in your patient, as this may select more resistant organisms. Comments and Limitations Three years of data were pooled to get sufficient numbers of isolates for each species. Most susceptibility patterns are relatively stable. For recent data on common isolates, please see the most recent annual antibiogram. Data were collected on isolates, not patients, due to software limitations. There is often more than one isolate from each patient. Some species are uncommon and the number of isolates is low. These are marked in red. Results are approximate, but are included to highlight typical treatment considerations or important resistance patterns. The Y axis and the number above each column indicate the percentage of isolates of that species that were fully susceptible to the antibiotic. Contacts For further information on antimicrobial susceptibility testing, please contact the Microbiologist-on-call, or one of us at the numbers below: Ghada Al-Rawahi MD FRCPC (64) ext 2394 galrawahi@cw.bc.ca David Goldfarb MD FRCPC (64) ext 7688 david.goldfarb@cw.bc.ca Jocelyn Srigley MD FRCPC (64) ext 528 jocelyn.srigley@cw.bc.ca Peter Tilley MD FRCPC (64) ext 6694 ptilley@cw.bc.ca July 28 th, 216 2

3 Achromobacter species Achromobacter species n= Acinetobacter species Acinetobacter species n= July 28 th, 216 3

4 Bacillus species Bacillus species n= Note the small sample size. Results are approximate. Burkholderia cepacia complex Burkholderia cepacia complex n= Note the small sample size. Results are approximate. B. cepacia complex organisms are resistant to aminoglycosides and colistin. July 28 th, 216 4

5 Campylobacter jejuni Campylobacter jejuni n= Erythromycin result also applies to azithromycin (EUCAST). Chryseobacterium species Chryseobacterium species n= Chryseobacteria are environmental organisms which carry metalo-beta-lactamases, rendering them resistant to most penicillins, cephalosporins and carbapenems. Treatment options are limited. Kirby, Journal of Clinical Microbiology 24. July 28 th, 216 5

6 Citrobacter freundii Citrobacter freundii n= *Note that Citrobacter freundii has a chromosomal AmpC beta-lactamase. While appearing susceptible to 3rd generation cephalosporins (such as cefotaxime) on testing, it may become resistant during therapy (Choi, Antimicrob Agents Chemother 52;3:995-28). For this reason, carbapenems are often used to treat invasive C. freundii infections. Citrobacter koseri Citrobacter koseri n= July 28 th, 216 6

7 Corynebacterium species 8 82 Corynebacterium species n= Note the small sample size. Results are approximate. Elizabethkingia species 8 Elizabethkingia species n= Elizabethkingia (previously named Flavibacterium and Chryseobacterium) are environmental organisms which carry metalo - beta-lactamases, rendering them resistant to most penicillins, cephalosporins and carbapenems. Treatment options are limited. July 28 th, 216 7

8 Enterobacter aerogenes 8 6 Enterobacter aerogenes n= Note that Enterobacter species have a chromosomal AmpC beta-lactamase. While appearing susceptible to 3rd generation cephalosporins (such as cefotaxime) on testing, they become resistant during therapy in about 1-2% of cases (Chow, Annals Int Med 115: ). For this reason, carbapenems are often used to treat invasive Enterobacter infections. Enterobacter cloacae complex Enterobacter cloacae complex n= Note that Enterobacter species have a chromosomal AmpC beta-lactamase. While appearing susceptible to 3rd generation cephalosporins (such as cefotaxime) on testing, they become resistant during therapy in about 1-2% of cases (Chow, Annals Int Med 115: ). For this reason, carbapenems are often used to treat invasive Enterobacter infections. Enterobacter cloacae complex includes E. cloacae, asburiae, kobei, hormaechei, ludwigii, nimipressuralis. July 28 th, 216 8

9 Enterococcus faecalis Enterococcus faecalis n= * Please note that E. faecalis is resistant to all cephalosporins and quinupristin/dalfopristin. Meropenem has poor activity (Edwards, Journal of Anticrobial Chemotherapy 1995). Enterococcus faecium Enterococcus faecium 89 n= Please note that E. faecium is resistant to all cephalosporins. Meropenem has poor activity (Edwards, Journal of Anticrobial Chemotherapy 1995). Results are from 215 only with ARO/VRE screening specimens excluded. Note small sample size. Results are approximate. July 28 th, 216 9

10 Escherichia coli Escherichia coli n= Haemophilus influenzae Haemophilus influenzae 96 n= July 28 th, 216 1

11 Klebsiella oxytoca Klebsiella oxytoca n= Klebsiella pneumoniae Klebsiella pneumoniae n= July 28 th,

12 Morganella morganii 8 8 Morganella morganii n= Pantoea species Pantoea species n= Note the small sample size. Results are approximate. July 28 th,

13 Propionibacterium species Propionibacterium species n= Note the small sample size. Results are approximate. Proteus mirabilis Proteus mirabilis n= July 28 th,

14 Pseudomonas aeruginosa 8 Pseudomonas aeruginosa n= Please note that cefotaxime, ceftriaxone and SXT are NOT effective for treatment of Pseudomonas aeruginosa infections. Data include patients with cystic fibrosis. Pseudomonas fluorescens group Pseudomonas fluorescens group n=68 75 July 28 th,

15 Pseudomonas putida group Pseudomonas putida group 93 n= Serratia marcescens 8 6 Serratia marcescens 99 9 n= *Note that Serratia marcescens has a chromosomal AmpC beta-lactamase. While appearing susceptible to 3rd generation cephalosporins (such as cefotaxime) on testing, there is concern that it may become resistant during therapy, although this is rare (Choi, Antimicrob Agents Chemother 52;3:995-28). For critically ill patients, meropenem may be a better option. If cefotaxime or ceftriaxone are used, and patient response is less than expected, please repeat cultures. July 28 th,

16 Salmonella species 88 Salmonella species n= Please note that first and second generation cephalosporins (e.g. cefazolin, cefuroxime) and aminoglycosides are ineffective against Salmonella species. Resistance against fluoroquinolones is increasing rapidly. July 28 th,

17 Staphylococcus aureus Staph aureus n= data only shown. Clinical isolates only - MRSA screens excluded *Note that penicillin susceptibility is not reported at C&W due to its rarity and the subjectivity of the test. Methicillin-Resistant Staphylococcus aureus 8 MRSA n= Clinical isolates only. 215 only. MRSA screens excluded. July 28 th,

18 Staphylococcus epidermidis (most common coagulase-negative Staphylococcus) Staphylococcus epidermidis n= Staphylococcus capitis (coagulase-negative) Staphylococcus capitis n= July 28 th,

19 Staphylococcus lugdunensis 8 6 Staphylococcus lugdunensis n= Stenotrophomonas maltophilia Stenotrophomonas maltophilia n= S. maltophilia carries chromosomal carbapenemases, and is resistant to meropenem and imipenem. July 28 th,

20 Streptococcus pyogenes (Group A Strep) Streptococcus pyogenes (Gp A Strep) n= *Penicillin or vancomycin resistance has not been reported for Streptococcus pyogenes. Streptococcus agalactiae (Group B Strep) Streptococcus agalactiae (Gp B Strep) n= Inducible MLSB resistance testing is performed at C&W Microbiology before reporting clindamycin results. July 28 th, 216 2

21 Streptococcus dysgalactiae (Groups C & G) Streptococcus dysgalactiae n= Streptococcus pneumoniae 8 Streptococcus pneumoniae 8 n= *Note that lower interpretive breakpoints are used for CSF isolates reflecting lower antibiotic levels. Erythromycin resistance also applies to azithromycin and clarithromycin. July 28 th,

22 Streptococcus mitis group (viridans Strep) Streptococcus mitis group n= Streptococcus anginosis group Streptococcus anginosis group n= Streptococcus anginosis group includes S. anginosis, constellatus and intermedius. July 28 th,

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine

2012 ANTIBIOGRAM. Central Zone Former DTHR Sites. Department of Pathology and Laboratory Medicine 2012 ANTIBIOGRAM Central Zone Former DTHR Sites Department of Pathology and Laboratory Medicine Medically Relevant Pathogens Based on Gram Morphology Gram-negative Bacilli Lactose Fermenters Non-lactose

More information

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital

2010 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Children s Hospital 2010 ANTIBIOGRAM University of Alberta Hospital and the Stollery Children s Hospital Medical Microbiology Department of Laboratory Medicine and Pathology Table of Contents Page Introduction..... 2 Antibiogram

More information

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2017 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2017 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016)

BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) BACTERIAL SUSCEPTIBILITY REPORT: 2016 (January 2016 December 2016) VA Palo Alto Health Care System April 14, 2017 Trisha Nakasone, PharmD, Pharmacy Service Russell Ryono, PharmD, Public Health Surveillance

More information

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services

2015 Antibiogram. Red Deer Regional Hospital. Central Zone. Alberta Health Services 2015 Antibiogram Red Deer Regional Hospital Central Zone Alberta Health Services Introduction. This antibiogram is a cumulative report of the antimicrobial susceptibility rates of common microbial pathogens

More information

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital

2009 ANTIBIOGRAM. University of Alberta Hospital and the Stollery Childrens Hospital 2009 ANTIBIOGRAM University of Alberta Hospital and the Stollery Childrens Hospital Division of Medical Microbiology Department of Laboratory Medicine and Pathology 2 Table of Contents Page Introduction.....

More information

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER

INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER INFECTIOUS DISEASES DIAGNOSTIC LABORATORY NEWSLETTER University of Minnesota Health University of Minnesota Medical Center University of Minnesota Masonic Children s Hospital May 2017 Printed herein are

More information

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose

2016 Antibiogram. Central Zone. Alberta Health Services. including. Red Deer Regional Hospital. St. Mary s Hospital, Camrose 2016 Antibiogram Central Zone Alberta Health Services including Red Deer Regional Hospital St. Mary s Hospital, Camrose Introduction This antibiogram is a cumulative report of the antimicrobial susceptibility

More information

RCH antibiotic susceptibility data

RCH antibiotic susceptibility data RCH antibiotic susceptibility data The following represent RCH antibiotic susceptibility data from 2008. This data is used to inform antibiotic guidelines used at RCH. The data includes all microbiological

More information

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016

Mercy Medical Center Des Moines, Iowa Department of Pathology. Microbiology Department Antibiotic Susceptibility January December 2016 Mercy Medical Center Des Moines, Iowa Department of Pathology Microbiology Department Antibiotic Susceptibility January December 2016 These statistics are intended solely as a GUIDE to choosing appropriate

More information

2015 Antibiotic Susceptibility Report

2015 Antibiotic Susceptibility Report Citrobacter freundii Enterobacter aerogenes Enterobacter cloacae Escherichia coli Haemophilus influenzenza Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIII NUMBER 1 July 2008 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell, SM (ASCP), Marti Roe SM (ASCP), Ann-Christine Nyquist MD, MSPH Are the bugs winning? The 2007

More information

CUMULATIVE ANTIBIOGRAM

CUMULATIVE ANTIBIOGRAM BC Children s Hospital and BC Women s Hospital & Health Centre CUMULATIVE ANTIBIOGRAM 2017 Division of Medical Microbiology Department of Pathology and Laboratory Medicine Page 1 of 5 GRAM-POSITIVE BACTERIA

More information

2016 Antibiotic Susceptibility Report

2016 Antibiotic Susceptibility Report Fairview Northland Medical Center and Elk River, Milaca, Princeton and Zimmerman Clinics 2016 Antibiotic Susceptibility Report GRAM-NEGATIVE ORGANISMS 2016 Gram-Negative Non-Urine The number of isolates

More information

Concise Antibiogram Toolkit Background

Concise Antibiogram Toolkit Background Background This toolkit is designed to guide nursing homes in creating their own antibiograms, an important tool for guiding empiric antimicrobial therapy. Information about antibiograms and instructions

More information

Antimicrobial Susceptibility Testing: Advanced Course

Antimicrobial Susceptibility Testing: Advanced Course Antimicrobial Susceptibility Testing: Advanced Course Cascade Reporting Cascade Reporting I. Selecting Antimicrobial Agents for Testing and Reporting Selection of the most appropriate antimicrobials to

More information

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities.

Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Table 1. Commonly encountered or important organisms and their usual antimicrobial susceptibilities. Gram-positive cocci: Staphylococcus aureus: *Resistance to penicillin is almost universal. Resistance

More information

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015

Aberdeen Hospital. Antibiotic Susceptibility Patterns For Commonly Isolated Organisms For 2015 Aberdeen Hospital Antibiotic Susceptibility Patterns For Commonly Isolated s For 2015 Services Laboratory Microbiology Department Aberdeen Hospital Nova Scotia Health Authority 835 East River Road New

More information

microbiology testing services

microbiology testing services microbiology testing services You already know Spectra Laboratories for a wide array of dialysis-related testing services. Now get to know us for your microbiology needs. As the leading provider of renal-specific

More information

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases 4 th and 5 th generation cephalosporins Naderi HR Associate professor of Infectious Diseases Classification Forth generation: Cefclidine, cefepime (Maxipime),cefluprenam, cefoselis,cefozopran, cefpirome

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXIX NUMBER 3 November 2014 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Marti Roe SM MLS (ASCP), Sarah Parker MD, Jason Child PharmD, and Samuel R.

More information

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS

THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS THE NAC CHALLENGE PANEL OF ISOLATES FOR VERIFICATION OF ANTIBIOTIC SUSCEPTIBILITY TESTING METHODS Stefanie Desmet University Hospitals Leuven Laboratory medicine microbiology stefanie.desmet@uzleuven.be

More information

Leveraging the Lab and Microbiology Department to Optimize Stewardship

Leveraging the Lab and Microbiology Department to Optimize Stewardship Leveraging the Lab and Microbiology Department to Optimize Stewardship Presented by: Andrew Martinez MLS(ASCP), MT(AMT), MBA Alaska Native Medical Center Microbiology Supervisor Maniilaq Health Center

More information

Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data

Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Recommendations Regarding Use of Rapid Blood Pathogen Identification Panel Data Trevor Van Schooneveld MD, Scott Bergman, PharmD, BCPS, Paul Fey, PhD, Mark Rupp, MD The Clinical Microbiology laboratory

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXXII NUMBER 6 September 2017 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine Dowell SM MLS (ASCP), Stacey Hamilton MT SM (ASCP), Samuel Dominguez MD PhD, Sarah Parker MD, and

More information

HOSPITAL-ACQUIRED INFECTIONS AND QASM PATIENTS

HOSPITAL-ACQUIRED INFECTIONS AND QASM PATIENTS Royal Australasian College of Surgeons Queensland Audit of Surgical Mortality (QASM) HOSPITAL-ACQUIRED INFECTIONS AND QASM PATIENTS (JULY 2011 TO JUNE 2016) Contact Queensland Audit of Surgical Mortality

More information

Antimicrobial susceptibility

Antimicrobial susceptibility Antimicrobial susceptibility PATTERNS Microbiology Department Canterbury ealth Laboratories and Clinical Pharmacology Department Canterbury District ealth Board March 2011 Contents Preface... Page 1 ANTIMICROBIAL

More information

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Antibiotic Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting Any substance of natural, synthetic or semisynthetic origin which at low concentrations kills or inhibits the growth of bacteria

More information

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.)

QUICK REFERENCE. Pseudomonas aeruginosa. (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Pseudomonas aeruginosa (Pseudomonas sp. Xantomonas maltophilia, Acinetobacter sp. & Flavomonas sp.) Description: Greenish gray colonies with some beta-hemolysis around each colony on blood agar (BAP),

More information

Antibiotic Stewardship Program (ASP) CHRISTUS SETX

Antibiotic Stewardship Program (ASP) CHRISTUS SETX Antibiotic Stewardship Program (ASP) CHRISTUS SETX Program Goals I. Judicious use of antibiotics Decrease use of broad spectrum antibiotics and deescalate use based on clinical symptoms Therapeutic duplication:

More information

TABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11

TABLE OF CONTENTS. Urine - Gram Positive Susceptibility Reporting 1 Staphylococcus species, MRSA...11 Policy #MI\ANTI\v23 Page 1 of 3 Section: Antimicrobial Susceptibility Testing Subject Title: Table of Contents Manual Issued by: LABORATORY MANAGER Original Date: January 10, 2000 Approved by: Laboratory

More information

HUSRES Annual Report 2007 Martti Vaara.

HUSRES Annual Report 2007 Martti Vaara. HUSRES Annual Report 2007 Martti Vaara www.huslab.fi www.intra.hus.fi The basis of this HUSRES 2007 report is the HUSLAB/Whonet database 2007, which contains susceptibility data on about 182.000 bacteria

More information

2015 Antimicrobial Susceptibility Report

2015 Antimicrobial Susceptibility Report Gram negative Sepsis Outcome Programme (GNSOP) 2015 Antimicrobial Susceptibility Report Prepared by A/Professor Thomas Gottlieb Concord Hospital Sydney Jan Bell The University of Adelaide Adelaide On behalf

More information

Childrens Hospital Antibiogram for 2012 (Based on data from 2011)

Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Childrens Hospital Antibiogram for 2012 (Based on data from 2011) Prepared by: Department of Clinical Microbiology, Health Sciences Centre For further information contact: Andrew Walkty, MD, FRCPC Medical

More information

Fundamental Concepts in the Use of Antibiotics. Case. Case. TM is a 24 year old male admitted to ICU after TBI and leg fracture from MVA ICU day 3

Fundamental Concepts in the Use of Antibiotics. Case. Case. TM is a 24 year old male admitted to ICU after TBI and leg fracture from MVA ICU day 3 Fundamental Concepts in the Use of Antibiotics Todd Miano, PharmD, MSCE Critical Care Pharmacist Pharmacoepidemiology Fellow Perelman School of Medicine at the University of Pennsylvania Case TM is a 24

More information

Intrinsic, implied and default resistance

Intrinsic, implied and default resistance Appendix A Intrinsic, implied and default resistance Magiorakos et al. [1] and CLSI [2] are our primary sources of information on intrinsic resistance. Sanford et al. [3] and Gilbert et al. [4] have been

More information

Study Type of PCR Primers Identified microorganisms

Study Type of PCR Primers Identified microorganisms Study Type of PCR Primers Identified microorganisms Portillo et al, Marín et al, Jacovides et al, Real-time multiplex PCR (SeptiFasta, Roche Diagnostics) 16S rr gene was amplified using conventional PCR.

More information

CF WELL Pharmacology: Microbiology & Antibiotics

CF WELL Pharmacology: Microbiology & Antibiotics CF WELL Pharmacology: Microbiology & Antibiotics Bradley E. McCrory, PharmD, BCPS Clinical Pharmacy Specialist Pulmonary Medicine Cincinnati Children s Hospital Medical Center January 26, 2017 Disclosure

More information

Antimicrobial Susceptibility Summary 2011

Antimicrobial Susceptibility Summary 2011 Antimicrobial Susceptibility Summary 2011 Clinical Microbiology Department of Pathology & Laboratory Medicine 45 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and Laboratory

More information

What s new in EUCAST methods?

What s new in EUCAST methods? What s new in EUCAST methods? Derek Brown EUCAST Scientific Secretary Interactive question 1 MIC determination MH-F broth for broth microdilution testing of fastidious microorganisms Gradient MIC tests

More information

Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland,

Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, Non-Susceptibility of Bacterial Pathogens Causing Hospital-Onset Pneumonia UK and Ireland, 2008-2016 Alicia Russell Federation of Infection Societies conference 14 th November 2018 alisia_russell BSAC

More information

Antimicrobial Susceptibility Summary 2012

Antimicrobial Susceptibility Summary 2012 Antimicrobial Susceptibility Summary 2012 Clinical Microbiology Department of Pathology & Laboratory Medicine 46 53 Antimicrobial Susceptibility Summary Clinical Microbiology Department of Pathology and

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST Version 8.0, valid from 018-01-01

More information

UNDERSTANDING THE ANTIBIOGRAM

UNDERSTANDING THE ANTIBIOGRAM UNDERSTANDING THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Indiana University School of Medicine - Evansville Evansville, IN April.Abbott@Deaconess.com WHAT WE WILL COVER Describe

More information

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards

The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards The Basics: Using CLSI Antimicrobial Susceptibility Testing Standards Janet A. Hindler, MCLS, MT(ASCP) UCLA Health System Los Angeles, California, USA jhindler@ucla.edu 1 Learning Objectives Describe information

More information

Research Article Susceptibility Pattern of Isolates from Surgical Ward Patients of A Tertiary Care Referral Hospital, Rawalpindi, Pakistan

Research Article Susceptibility Pattern of Isolates from Surgical Ward Patients of A Tertiary Care Referral Hospital, Rawalpindi, Pakistan Cronicon OPEN ACCESS MICROBIOLOGY Research Article Susceptibility Pattern of Isolates from Surgical Ward Patients of A Tertiary Care Referral Hospital, Rawalpindi, Umer Shujat*, Aamer Ikram, Shahid A Abbasi,

More information

Cleaning and Disinfection Protocol Vegetative Bacteria

Cleaning and Disinfection Protocol Vegetative Bacteria Cleaning and Disinfection Protocol Vegetative Bacteria This document has been developed in accordance with current applicable infection control and biosecurity guidelines. It is intended for use as a guideline

More information

In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone

In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Feb. 993, p. 39-353 0066-0/93/0039-05$0.00/0 Copyright 993, American Society for Microbiology Vol. 37, No. In Vitro Antimicrobial Activity of, a Novel Azabicyclo-Naphthyridone

More information

Vitek QC Sets. Vitek 2 Identification QC Sets

Vitek QC Sets. Vitek 2 Identification QC Sets Vitek 2 Identification QC Sets MicroBioLogics is selling two types of Vitek 2 microorganism identification sets. They are listed below in two columns. The first column lists the 2008 quality control microorganisms

More information

TECHNICAL BULLETIN PURELL Advanced with Aloe Instant Hand Sanitizer

TECHNICAL BULLETIN PURELL Advanced with Aloe Instant Hand Sanitizer TECHNICAL BULLETIN PURELL Advanced with Aloe Instant Hand Sanitizer INDICATIONS: Hand sanitizer to help reduce bacteria on the skin that could cause disease. Recommended for repeated use. DIRECTIONS: Place

More information

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE)

CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) CARBAPENEM RESISTANT ENTEROBACTERIACEAE (KPC CRE) Bartsch SM et al. Potential economic burden of carbapenem-resistent Enterobacteriaceae (CRE) in the United States. Clin Microbiol Infect 2017;23(1):48e9-e16.

More information

Cleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria

Cleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria Cleaning and Disinfection Protocol for Gram-Negative and Gram-Positive Bacteria, including Antibiotic Resistant Bacteria This document has been developed in accordance with current applicable infection

More information

Routine internal quality control as recommended by EUCAST Version 3.1, valid from

Routine internal quality control as recommended by EUCAST Version 3.1, valid from Routine internal quality control as recommended by EUCAST Version.1, valid from 01-01-01 Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus

More information

EUCAST recommended strains for internal quality control

EUCAST recommended strains for internal quality control EUCAST recommended strains for internal quality control Escherichia coli Pseudomonas aeruginosa Staphylococcus aureus Enterococcus faecalis Streptococcus pneumoniae Haemophilus influenzae ATCC 59 ATCC

More information

What s next in the antibiotic pipeline?

What s next in the antibiotic pipeline? What s next in the antibiotic pipeline? Jennifer Tieu, Pharm.D., BCPS Clinical Pearls OSHP Spring Meeting Mercy Hospital April 13, 2018 Objective 2 Describe the drug class and mechanism of action of antibiotics

More information

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST

Help with moving disc diffusion methods from BSAC to EUCAST. Media BSAC EUCAST Help with moving disc diffusion methods from BSAC to EUCAST This document sets out the main differences between the BSAC and EUCAST disc diffusion methods with specific emphasis on preparation prior to

More information

Policy # MI_AST Department of Microbiology. Page Quality Manual

Policy # MI_AST Department of Microbiology. Page Quality Manual Department of Microbiology Version: 2.0 CURRENT 1 of 160 Prepared by QA Committee Issued by: Laboratory Manager Revision Date: 2/26/2018 Approved by Laboratory Director: Annual Review Date: 5/1/2018 Microbiologist-in-Chief

More information

Antimicrobial Stewardship Strategy: Antibiograms

Antimicrobial Stewardship Strategy: Antibiograms Antimicrobial Stewardship Strategy: Antibiograms A summary of the cumulative susceptibility of bacterial isolates to formulary antibiotics in a given institution or region. Its main functions are to guide

More information

CONTAGIOUS COMMENTS Department of Epidemiology

CONTAGIOUS COMMENTS Department of Epidemiology VOLUME XXVII NUMBER 6 July 2012 CONTAGIOUS COMMENTS Department of Epidemiology Bugs and Drugs Elaine B. Dowell SM, MLS (ASCP); Sarah K. Parker, MD; James K. Todd, MD Each year the Children s Hospital Colorado

More information

Advanced Practice Education Associates. Antibiotics

Advanced Practice Education Associates. Antibiotics Advanced Practice Education Associates Antibiotics Overview Difference between Gram Positive(+), Gram Negative(-) organisms Beta lactam ring, allergies Antimicrobial Spectra of Antibiotic Classes 78 Copyright

More information

Understanding the Hospital Antibiogram

Understanding the Hospital Antibiogram Understanding the Hospital Antibiogram Sharon Erdman, PharmD Clinical Professor Purdue University College of Pharmacy Infectious Diseases Clinical Pharmacist Eskenazi Health 5 Understanding the Hospital

More information

UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM

UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM UNDERSTANDING YOUR DATA: THE ANTIBIOGRAM April Abbott, PhD, D(ABMM) Deaconess Health System Evansville, IN April.Abbott@Deaconess.com Special thanks to Dr. Shelley Miller for UCLA data WHAT WE WILL COVER

More information

Michael Hombach*, Guido V. Bloemberg and Erik C. Böttger

Michael Hombach*, Guido V. Bloemberg and Erik C. Böttger J Antimicrob Chemother 2012; 67: 622 632 doi:10.1093/jac/dkr524 Advance Access publication 13 December 2011 Effects of clinical breakpoint changes in CLSI guidelines 2010/2011 and EUCAST guidelines 2011

More information

EARS Net Report, Quarter

EARS Net Report, Quarter EARS Net Report, Quarter 4 213 March 214 Key Points for 213* Escherichia coli: The proportion of patients with invasive infections caused by E. coli producing extended spectrum β lactamases (ESBLs) increased

More information

SYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data

SYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data 508 SYMMETRY FOAMING HAND SANITIZER with Aloe & Vitamin E Technical Data Physical Properties Active Ingredient: Ethyl Alcohol 62% (70% v/v) Appearance: Clear, Colorless Solution Fragrance: Floral Form:

More information

Antimicrobial Resistance Trends in the Province of British Columbia

Antimicrobial Resistance Trends in the Province of British Columbia 655 West 12th Avenue Vancouver, BC V5Z 4R4 Tel 604.707.2443 Fax 604.707.2441 www.bccdc.ca Antimicrobial Resistance Trends in the Province of British Columbia 2013 Prepared by the Do Bugs Need Drugs? Program

More information

SHC Clinical Pathway: HAP/VAP Flowchart

SHC Clinical Pathway: HAP/VAP Flowchart SHC Clinical Pathway: Hospital-Acquired and Ventilator-Associated Pneumonia SHC Clinical Pathway: HAP/VAP Flowchart v.08-29-2017 Diagnosis Hospitalization (HAP) Pneumonia develops 48 hours following: Endotracheal

More information

Antibacterial Resistance In Wales

Antibacterial Resistance In Wales A Report from Public Health Wales Antimicrobial Resistance Programme Surveillance Unit: Antibacterial Resistance In Wales 2005-2012 Authors: Maggie Heginbothom Robin Howe & Catherine Thomas Version: 1

More information

Epidemiology and Microbiology of Surgical Wound Infections

Epidemiology and Microbiology of Surgical Wound Infections JOURNAL OF CLINICAL MICROBIOLOGY, Feb. 2000, p. 918 922 Vol. 38, No. 2 0095-1137/00/$04.00 0 Copyright 2000, American Society for Microbiology. All Rights Reserved. Epidemiology and Microbiology of Surgical

More information

Antibacterial Resistance In Wales

Antibacterial Resistance In Wales A Report from Public Health Wales Antimicrobial Resistance Programme Surveillance Unit: Antibacterial Resistance In Wales 2005-2013 Authors: Maggie Heginbothom and Robin Howe Version: 1 Antibacterial Resistance

More information

ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014

ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 ANTIMICROBIAL RESISTANCE SURVEILLANCE FROM SENTINEL PUBLIC HOSPITALS, SOUTH AFRICA, 2014 Olga Perovic, 1,2 Verushka Chetty 1 & Samantha Iyaloo 1 1 National Institute for Communicable Diseases, NHLS 2 Department

More information

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges

Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Educating Clinical and Public Health Laboratories About Antimicrobial Resistance Challenges Janet Hindler, MCLS MT(ASCP) UCLA Medical Center jhindler@ucla.edu also working as a consultant with the Association

More information

BactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21

BactiReg3 Event Notes Module Page(s) 4-9 (TUL) Page 1 of 21 www.wslhpt.org 2601 Agriculture Drive Madison, WI 53718 (800) 462-5261 (608) 265-1111 2015-BactiR Reg3 Shipment Date: September 14, 2015 Questions or comments should be directed to Amanda Weiss at 800-462-5261

More information

European Committee on Antimicrobial Susceptibility Testing

European Committee on Antimicrobial Susceptibility Testing European Committee on Antimicrobial Susceptibility Testing Routine and extended internal quality control as recommended by EUCAST Version 5.0, valid from 015-01-09 This document should be cited as "The

More information

IV Antibiotics for Lyme Disease (Ceftriaxone, Cefotaxime sodium, Doxycycline, Penicillin G potassium)

IV Antibiotics for Lyme Disease (Ceftriaxone, Cefotaxime sodium, Doxycycline, Penicillin G potassium) Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.15 Subject: IV Antibiotics Lyme Disease Page: 1 of 9 Last Review Date: November 30, 2018 IV Antibiotics

More information

Appropriate antimicrobial therapy in HAP: What does this mean?

Appropriate antimicrobial therapy in HAP: What does this mean? Appropriate antimicrobial therapy in HAP: What does this mean? Jaehee Lee, M.D. Kyungpook National University Hospital, Korea KNUH since 1907 Presentation outline Empiric antimicrobial choice: right spectrum,

More information

Drug Class Prior Authorization Criteria Intravenous Antibiotics

Drug Class Prior Authorization Criteria Intravenous Antibiotics Drug Class Prior Authorization Criteria Intravenous Antibiotics Line of Business: Medicaid P&T Approval Date: August 15, 2018 Effective Date: October 1, 2018 This drug class prior authorization criteria

More information

Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities

Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities REVIEW Doripenem: A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities Fiona Walsh Department of Clinical Microbiology, Trinity College Dublin, Dublin, Ireland

More information

ADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao

ADC 2016 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao ADC 216 Report on Bacterial Resistance in Cultures from SEHOS and General Practitioners in Curaçao Willemstad, November 217 Authors: Radjin Steingrover clinical microbiologist, head dpt. Microbiology ADC

More information

Helen Heffernan. Rosemary Woodhouse

Helen Heffernan. Rosemary Woodhouse ANTIMICROBIAL RESISTANCE AMONG GRAM-NEGATIVE BACILLI FROM BACTERAEMIA, 2007 Helen Heffernan Rosemary Woodhouse Antibiotic Reference Laboratory Communicable Disease Group Institute of Environmental Science

More information

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults

National Clinical Guideline Centre Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults National Clinical Guideline Centre Antibiotic classifications Pneumonia Diagnosis and management of community- and hospital-acquired pneumonia in adults Clinical guideline 191 Appendix N 3 December 2014

More information

Monitoring of AMR in Russia

Monitoring of AMR in Russia Monitoring of AMR in Russia Surveillance studies conducted by Institute of Antimicrobial Chemotherapy (IAC) Centre for Monitoring of Antimicrobial Resistance (CMAR) Prospective surveillance studies on

More information

Antimicrobial Susceptibility Testing: The Basics

Antimicrobial Susceptibility Testing: The Basics Antimicrobial Susceptibility Testing: The Basics Susan E. Sharp, Ph.D., DABMM, FAAM Director, Airport Way Regional Laboratory Director, Regional Microbiology and Molecular Infectious Diseases Laboratories

More information

Guidelines for Laboratory Verification of Performance of the FilmArray BCID System

Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Guidelines for Laboratory Verification of Performance of the FilmArray BCID System Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory

More information

ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES

ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES ANTIMICROBIAL STEWARDSHIP IN LONG TERM CARE FACILITIES ANTIMICROBIAL STEWARDSHIP COLLABORATIVE COLORADO HOSPITAL ASSOCIATION MARCH 23, 2016 Bridget Olson, RPh Infectious Disease Pharmacist, Sharp Coronado

More information

British Society for Antimicrobial Chemotherapy

British Society for Antimicrobial Chemotherapy British Society for Antimicrobial Chemotherapy BSAC to actively support the EUCAST Disc Diffusion Method for Antimicrobial Susceptibility Testing in preference to the current BSAC Disc Diffusion Method

More information

British Society for Antimicrobial Chemotherapy

British Society for Antimicrobial Chemotherapy British Society for Antimicrobial Chemotherapy Standing Committee on Susceptibility Testing Version 13.0, 10-06-2014 Content Page Additional information Changes in version 13 2 Suggestions for appropriate

More information

Antibacterial Resistance in Wales

Antibacterial Resistance in Wales Antibacterial Resistance in Wales 2006-2015 June 2016 Microbiology Division, Public Health Wales Table of Contents Table of Contents... 1 Section 1: Introduction... 2 Section 2: Key points of interest...

More information

The Cost of Antibiotic Resistance: What Every Healthcare Executive Should Know

The Cost of Antibiotic Resistance: What Every Healthcare Executive Should Know The Cost of Antibiotic Resistance: What Every Healthcare Executive Should Know JCR National Infection Prevention and Control Conference 2009 Mastering Powerful and Practical Infection Prevention Strategies

More information

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck! Medicinal Chemistry 561P 2 st hour Examination May 6, 2013 NAME: KEY Good Luck! 2 MDCH 561P Exam 2 May 6, 2013 Name: KEY Grade: Fill in your scantron with the best choice for the questions below: 1. Which

More information

Antimicrobial susceptibility of pathogens from Canadian hospitals: results of the CANWARD study

Antimicrobial susceptibility of pathogens from Canadian hospitals: results of the CANWARD study J Antimicrob Chemother 2013; 68 Suppl 1: i7 i22 doi:10.1093/jac/dkt022 Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007 11 study George G. Zhanel 1,2

More information

EUCAST expert rules in antimicrobial susceptibility testing

EUCAST expert rules in antimicrobial susceptibility testing REVIEW BACTERIOLOGY EUCAST expert rules in antimicrobial susceptibility testing R. Leclercq 1,2, R. Cantón 2,3,4, D. F. J. Brown 4, C. G. Giske 2,4,5, P. Heisig 2,6, A. P. MacGowan 4,7, J. W. Mouton 4,8,

More information

Antimicrobial Resistance Advisory Workgroup (ARAW) Members

Antimicrobial Resistance Advisory Workgroup (ARAW) Members Antimicrobial Resistance Advisory Workgroup (ARAW) Members Jackie Aguilar, BSN, RN Anne Diefendorf, MS, RD Ella Martin, MD Lisa Tibbitts, RN, BSN, MSNed, BC Bobbie Bagley, RN, MS, MCH, CPH Apara Dave,

More information

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention

Infection Prevention Highlights for the Medical Staff. Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Highlights for the Medical Staff Pamela Rohrbach MSN, RN, CIC Director of Infection Prevention Standard Precautions every patient every time a. Hand Hygiene b. Use of Personal Protective Equipment (PPE)

More information

Principles of Antibiotics Use & Spectrum of Some

Principles of Antibiotics Use & Spectrum of Some Principles of Antibiotics Use & Spectrum of Some Rabee Adwan. MD Infectious Diseases Consultant (Pediatric and Adult) Head Of ID Unit and IPAC Committee- AL-Makassed Hospital-AlQuds Head of IPAC Committee

More information

Management of Hospital-acquired Pneumonia

Management of Hospital-acquired Pneumonia Management of Hospital-acquired Pneumonia Adel Alothman, MB, FRCPC, FACP Asst. Professor, COM, KSAU-HS Head, Infectious Diseases, Department of Medicine King Abdulaziz Medical City Riyadh Saudi Arabia

More information

Antimicrobial Stewardship:

Antimicrobial Stewardship: Antimicrobial Stewardship: Inpatient and Outpatient Elements Angela Perhac, PharmD afperhac@carilionclinic.org Disclosure I have no relevant finances to disclose. Objectives Review the core elements of

More information

Antimicrobial susceptibility testing challenges. Linda Joyce St Vincent s Hospital Melbourne

Antimicrobial susceptibility testing challenges. Linda Joyce St Vincent s Hospital Melbourne Antimicrobial susceptibility testing challenges Linda Joyce St Vincent s Hospital Melbourne Bacteria/antimicrobials without breakpoints (B.A.W.B.S.) Enterobacteriacae Pseudomonas aeruginosa, Acinetobacter

More information

A Multi-Laboratory Study of the BIOMIC Automated Well Reading Instrument versus

A Multi-Laboratory Study of the BIOMIC Automated Well Reading Instrument versus JCM Accepts, published online ahead of print on 13 March 2013 J. Clin. Microbiol. doi:10.1128/jcm.03088-12 Copyright 2013, American Society for Microbiology. All Rights Reserved. 1 2 3 A Multi-Laboratory

More information

Antimicrobial Susceptibility Patterns

Antimicrobial Susceptibility Patterns Antimicrobial Susceptibility Patterns KNH SURGERY Department Masika M.M. Department of Medical Microbiology, UoN Medicines & Therapeutics Committee, KNH Outline Methodology Overall KNH data Surgery department

More information